Reviewer's report

**Title:** Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial.

**Version:** 2  **Date:** 21 April 2013

**Reviewer:** Karim Brohi

**Reviewer's report:**

This is a well written manuscript describing the results of a clinical trial of TXA in traumatic brain injury. The trial is timely and appears well conducted. It is reported in accordance with PRISMA guidelines. The resultant data are important for the design and conduct of future trials of TXA in TBI.

I have only minor comments -

Why was coagulopathy an exclusion criteria? This should be explained in the text.

What was the rationale for making PIH the primary outcome measure - the authors should specify this.

Were these isolated head injuries or part of multiple trauma? Can the authors provide some indication of injury severity or give an overview of other injuries if they include polytrauma patients.

The abstract should include that this is an RCT in the methods section.

**Level of interest:** An article of outstanding merit and interest in its field.

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests